Drug Trial Radar · NCT07215702
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Feb 11, 2027
Study completion Feb 11, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.
Conditions
- Sepsis
- Acute Kidney Injury
Interventions
AZD4144Drug
Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.
PlaceboDrug
Intravenous solution of Placebo will be administered to randomised participants according to the treatment arm to which they have been assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl).Time frame: During the treatment period.
Locations
74 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Newport Beach, California · Recruiting
Research Site
Kansas City, Kansas · Recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
The Bronx, New York · Recruiting
Research Site
The Bronx, New York · Recruiting
Research Site
The Bronx, New York · Recruiting
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Winston-Salem, North Carolina · Recruiting
Research Site
Corvallis, Oregon · Withdrawn
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Not yet recruiting
Research Site
Charleston, South Carolina · Recruiting
Research Site
Salt Lake City, Utah · Withdrawn
Research Site
CABA, Argentina · Withdrawn
Research Site
Ciudad de Buenos Aires, Argentina · Recruiting
Research Site
La Plata, Argentina · Recruiting
Research Site
Rosario, Argentina · Recruiting
Research Site
Brussels, Belgium · Recruiting
Research Site
Genk, Belgium · Recruiting
Research Site
Jette, Belgium · Recruiting
Research Site
Ottignies, Belgium · Recruiting
Research Site
Lévis, Quebec, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Withdrawn
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Québec, Quebec, Canada · Recruiting
Research Site
Québec, Quebec, Canada · Not yet recruiting
Research Site
Brno, Czechia · Not yet recruiting
Research Site
Kolín, Czechia · Recruiting
Research Site
Prague, Czechia · Withdrawn
Research Site
Prague, Czechia · Recruiting
Research Site
Aarhus N, Denmark · Withdrawn
Research Site
Gistrup, Denmark · Recruiting
Research Site
Hvidovre, Denmark · Recruiting
Research Site
Angers, France · Withdrawn
Research Site
Brive-la-Gaillarde, France · Not yet recruiting
Research Site
La Roche-sur-Yon, France · Recruiting
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.